Apr 25, 2017

Notice regarding Cancellation of Treasury Stocks

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
Chairman & CEO: Osamu Nagayama
Inquiries to: Masahiko Uchida,
General Manager, Corporate Communications Dept.
Tel:+81-(0)3-3273-0881

Chugai Pharmaceutical Co., Ltd. (the “Company”) hereby announces that, at the meeting of its Board of Directors held on April 25, 2017, the Directors decided to cancel the treasury stocks as follows.

  1. Purposes and Reasons of the cancellation of treasury stocks
    For the purpose of maintaining the appropriate number of all issued shares, the Directors decided to cancel the treasury stocks
  2. Outline of the treasury stock cancellation
    • Class of shares of stock to be cancelled: Common stock of the Company
    • Number of shares of stock to be cancelled: 123,000
      (Ratio against the number of all issued shares before cancellation : 0.02%)
    • Date of cancellation : April 28, 2017

(Reference)
Since the payment procedure for the issuance of 123,000 new shares as restricted stock compensation plan, which was resolved at the meeting of its Board of Directors held on March 23, 2017, was completed on April 21, 2017, the number of all issued shares after the cancellation shall be 559,685,889 which is the same number of shares before the issuance of the new shares. For further details, please refer to “Notice regarding Issuance of New Shares as Restricted Stock Compensation Plan” dated March 23, 2017.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Koki Harada
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top